Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q4 FY26
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
2
Neutral
10
Bullish
2
Bearish
2
Neutral
34
Bullish
10
Bearish
0
Neutral
24
Bullish
8
Discovery themes featuring this stock
GSP Crop Science Limited is an integrated, research-driven Indian agrochemical company manufacturing insecticides, herbicides, fungicides and plant growth regulators across formulations and technicals, operating five domestic manufacturing facilities and exporting to 37 countries. The company combines in-house technical synthesis and formulation R&D with a broad distributor network and a growing branded B2C presence under multiple owned brands.
GSP Crop Science has developed a differentiated IP-led strategy with 102 granted patents and 108 pending applications, commercialized 12 patented products to date, and achieved patented-product contribution near 20% of revenues in FY26; management targets steady annual launches and significant uplift in patented-product mix over the next three years.
Financially, the company delivered consolidated 9M FY26 revenue of INR 1,114 crore (up 14% year-on-year), EBITDA of INR 153.8 crore (up 32%) and PAT of INR 75.1 crore (up 26%), with EBITDA and PAT margin expansion driven by higher B2C branded sales and premium patented-product mix in the portfolio.
GSP Crop Science demonstrates capability to scale: technical plant utilizations are ~70–75% with formulations seasonal at 30–40% and management projecting peak revenue potential near INR 1,900–2,000 crore via de-bottlenecking and new product introductions, indicating a clear pathway to higher utilization and revenue density.
The company’s growth is supported by strategic international expansion — a Brazil subsidiary and focused registrations in Latin America and Africa — and partnerships with established co-marketeers that accelerate adoption of patented combinations and broaden distribution, positioning GSP Crop Science to capture higher-margin opportunities.
Industrial Manufacturing
Industrial Products
1,890 Cr
Moderate Risk
1.7
45.9
0.1
2.5
399.00
327.35
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
GSP Crop Science Ltd (GSPCROP) is currently trading at 415.25 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
GSP Crop Science Limited is an integrated, research-driven Indian agrochemical company manufacturing insecticides, herbicides, fungicides and plant growth regulators across formulations and technicals, operating five domestic manufacturing facilities and exporting to 37 countries. The company combines in-house technical synthesis and formulation R&D with a broad distributor network and a growing branded B2C presence under multiple owned brands. GSP Crop Science has developed a differentiated IP-led strategy with 102 granted patents and 108 pending applications, commercialized 12 patented products to date, and achieved patented-product contribution near 20% of revenues in FY26; management targets steady annual launches and significant uplift in patented-product mix over the next three years. Financially, the company delivered consolidated 9M FY26 revenue of INR 1,114 crore (up 14% year-on-year), EBITDA of INR 153.8 crore (up 32%) and PAT of INR 75.1 crore (up 26%), with EBITDA and PAT margin expansion driven by higher B2C branded sales and premium patented-product mix in the portfolio. GSP Crop Science demonstrates capability to scale: technical plant utilizations are ~70–75% with formulations seasonal at 30–40% and management projecting peak revenue potential near INR 1,900–2,000 crore via de-bottlenecking and new product introductions, indicating a clear pathway to higher utilization and revenue density. The company’s growth is supported by strategic international expansion — a Brazil subsidiary and focused registrations in Latin America and Africa — and partnerships with established co-marketeers that accelerate adoption of patented combinations and broaden distribution, positioning GSP Crop Science to capture higher-margin opportunities.
Over the past 52 weeks, GSP Crop Science Ltd has traded between a low of ₹327.35 and a high of ₹399.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
GSP Crop Science Ltd has a market capitalization of approximately 1,890.06. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
GSP Crop Science Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 1.74 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,890.06 Cr, GSP Crop Science Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
GSP Crop Science Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of GSP Crop Science Ltd is 1.74. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The board approved the unaudited financial results for Q3 and the nine months ended December 31, 2025. It also approved the sale of 66,740.60 sq. meters of industrial land to a promoter group company for ₹23.65 crore.
The total IPO size is ₹400 crore. This includes a fresh issue of shares worth ₹240 crore and an Offer for Sale (OFS) of shares valued at ₹160 crore by existing promoters.
The IPO will be open for public subscription from March 16 to March 18, 2026.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
971.65 | 2,088 Cr | 73.95 | 12.41 | 0.00 | 17.45 | 23.36 | 13.36 | ||
144.35 | 1,956 Cr | 19.53 | 2.83 | 0.00 | 11.18 | 14.15 | 5.85 | ||
270.40 | 1,925 Cr | 32.84 | 3.71 | 0.09 | 5.86 | 11.04 | 5.88 | ||
368.10 | 1,890 Cr | 1.74 | 2.46 | 0.15 | 18.80 | 19.00 | 0.00 | ||
1195.55 | 1,827 Cr | 94.58 | 8.48 | 0.00 | 13.79 | 15.11 | 8.17 | ||
12300.00 | 1,786 Cr | 33.65 | 6.45 | 1.62 | 17.32 | 23.70 | 12.00 | ||
327.00 | 1,725 Cr | 2.79 | 1.23 | 1.77 | 7.64 | 9.65 | 22.45 | ||
| Median: 7 Co. | — | 368.10 | 1,890 Cr | 32.84 | 3.71 | 0.09 | 13.79 | 15.11 | 8.17 |
Earnings Call Transcript
Transcript of Q3 FY26 post-results call (held Apr 17, 2026) reporting 9M revenue of INR 1,114 Cr, EBITDA INR 153 Cr (+32% YoY), PAT INR 75 Cr (vs INR 59.6 Cr); exceptional provision INR 4.5 Cr; business mix D-B2B 40%/D-B2C 40%/export 20%; 102 patents granted.
Earnings Presentation
GSP Crop Science filed an investor presentation for Q3 & 9M FY26 unaudited standalone and consolidated results: 9M consolidated revenue +14% to ₹11,146m and EBITDA +32% to ₹1,538m; standalone revenue +9% to ₹11,766m and EBITDA +23% to ₹1,296m.
